Cargando…

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

Detalles Bibliográficos
Autores principales:	Sharman, J. P., Jurczak, W., Coombs, C. C., Hill, M., Wang, D., Ku, N. C., Guntur, A., Shahda, S., Leow, C. C., Ghia, P., Mato, A. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429640/ http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64

Ejemplares similares

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
por: Mato, Anthony R., et al.
Publicado: (2022)

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
por: Cohen, Jonathon, et al.
Publicado: (2023)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
por: Montillo, Marco, et al.
Publicado: (2019)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
por: Eyre, T. A., et al.
Publicado: (2022)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
por: Egle, Alexander, et al.
Publicado: (2019)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region
por: Bott, Patricia, et al.
Publicado: (2022)

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL
por: Kadkol, Shrihari S., et al.
Publicado: (2021)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vdma057tb00fere4ha1pm9smh3